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INTRODUCTION
Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune disease, characterized by infl ammatory destruction and loss of intrahepatic bile ducts. Th e disease usually progresses slowly and may eventually lead to cirrhosis and its associated complications ( 1, 2 ) .
While the standard of care treatment ursodeoxycholic acid (UDCA) ( 2-4 ) has been found to improve survival ( 5-7 ), 20-50% of patients respond sub-optimally to this treatment (8) (9) (10) (11) (12) (13) . Studies over the past decades suggest that nowadays only a minority of ~15% of patients have evidence of advanced disease at presentation ( 12, (14) (15) (16) and that UDCA treatment is associated with a much slower histological disease progression than when patients are left untreated (17) (18) (19) . However, the cumulative incidence of cirrhosis over a 10-year follow-up in a recent large cohort study was ~40% ( 14 ) . Th is indicates that a substantial proportion of PBC patients might still face a risk of cirrhosis-associated complications at some point during their disease.
Cirrhosis-associated complications are likely to be negatively correlated with prognosis ( 20, 21 ) . Few studies have specifically evaluated the incidence of and risk factors for major cirrhosisassociated complications such as ascites, encephalopathy, and gastrointestinal bleeding in patients with PBC (22) (23) (24) (25) (26) . These studies either included small populations or a large majority of untreated patients, or did not provide detailed information regarding the spectrum of potential complications and the associated outcome. In light of the near universal treatment with UDCA for PBC today, better knowledge of the risk and impact of major cirrhosis-associated complications in a UDCA-treated population of patients with PBC is important and could be helpful for patient counseling and therapeutic decisions.
In this study we aimed to assess the incidence and risk factors for major, non-neoplastic hepatic complications in a large, internationally representative cohort of UDCA-treated PBC patients. Second, we aimed to assess potential diff erential eff ects of such events on long-term prognosis. Finally, we were interested to assess potential changes over time in the incidence and the prognostic impact of these complications.
METHODS

Population and study design
For the current study, patient data from 15 liver units across 10 countries in Europe and Northern America that are engaged in the Global PBC Study Group, were included. Individual patient data from long-term follow-up cohorts were combined. In the individual participating centers, most data were collected prospectively, usually over several decades. To ensure a uniform database, additional data were collected retrospectively when indicated. Only UDCA-treated patients with an established diagnosis of PBC in accordance with internationally accepted guidelines ( 2, 3 ) were eligible for inclusion in this study.
Individuals were excluded from analysis in case of insuffi cient follow up data (<6 months follow-up or <2 visits recorded), when dates of starting treatment or clinical events were unknown and when PBC-autoimmune hepatitis overlap syndrome ( 3 ) or other concomitant liver disease was present. To ensure reliable risk factor analysis, occurrence of an hepatic complication within the fi rst year of follow-up or before the start of UDCA therapy, was also reason to omit patients from analysis.
Diligent eff orts, including individual center visits to review the historical medical charts, were made to ensure data completeness. Th is study was conducted in accordance with the Declaration of Helsinki. Th e protocol was approved by the institutional research board of the corresponding center and at all participating centers as per local regulations.
Data collection
Baseline was set at the moment of starting UDCA therapy. Th e following clinical and biochemical data were collected: date of birth; sex; date of PBC diagnosis; liver biopsy; treatment (type, dosage, and duration), baseline antimitochondrial antibody status, baseline and yearly biochemistry (serum alkaline phosphatase, total bilirubin, alanine aminotransferase, aspartate aminotransferase (AST), albumin, γ -glutamyl transpeptidase, and platelets), and clinical outcomes (death, liver transplantation, hepatocellular carcinoma, ascites, variceal bleeding, and hepatic encephalopathy).
Histological baseline information was taken into account when a liver biopsy was available within 1 year from baseline. Histological disease severity was classifi ed according to the Ludwig and Scheuer classifi cation ( 27 ) . Stage I and II were considered to be early stage disease. Stage III and IV were classifi ed as advanced disease. Biochemically early vs. advanced disease was classifi ed according to serum bilirubin and albumin levels ( 28 ) .
Patients were followed according to the standard follow-up visit scheme of the participating centers. Th is usually included a clinic visit every 12 months for early disease stages and every 6 months for patients with advanced disease. Only those Global PBC Study Group centers for which data on complications were available participated in this study. Data of the original cohorts were collected to 31 December 2012 ( 29 ) . For three centers more recently joining the study group, data were collected up to 31 December 2015 ( Supplementary Table 1 online).
Hepatic complications
Data regarding the following cirrhosis-associated complications were collected: gastrointestinal variceal bleeding; ascites; and hepatic encephalopathy, whichever came fi rst. Ascites was deemed to be present when ascitic fl uid was confi rmed by abdominal imaging or in the event of prescribed diuretic treatment for clinically obvious ascites. A diagnosis of hepatic encephalopathy was based on expert (physician) opinion and was scored present or not present. Variceal bleeding was defi ned as hematemesis or melena due to endoscopically documented hemorrhage originating from gastro-esophageal varices.
Statistical analysis
Th e primary outcome of this study was defi ned as the fi rst occurrence of variceal bleeding, ascites, or hepatic encepha-lopathy. Patients without these complications were censored at time of last follow-up, liver transplantation, or death. For survival analyses, a combined end point of liver transplantation and death was used. Th e signifi cance of biochemical response to UDCA was analyzed using the Barcelona, Paris, Rotterdam, and Toronto biochemical criteria, and the recently published GLOBE and UK-PBC scores (8) (9) (10) (11) 13, 30, 31 ) . Th e risk of complications was also analyzed according to the AST to platelet ratio index (APRI) at 1 year of follow-up, which was also dichotomized according to the cut-point proposed by Trivedi et al. ( 16 ) . Univariate and multivariable Cox proportional hazards models were fi t to assess risk factors of patient characteristics and laboratory covariates on hepatic complications, and to assess covariates at time of a major hepatic complication that were associated with liver transplantation or death. In these analyses, we deliberately chose to not include histological disease stage as a variable, given there was no histological information for nearly 40% of the study population. A clockreset approach was used to visualize the impact of a fi rst hepatic complication on survival. Th e eff ect was assessed by timedependent Cox regression analyses. In this approach patients who had a major hepatic complication were switched to a new survival curve which was then reset as time 0 for their further follow-up ( 32 ) . To identify a subgroup of patients with a more favorable survival aft er occurrence of a major non-neoplastic hepatic complication, we fi rst tested the prognostic value of variables in univariate Cox regression analyses. We therefore also dichotomized laboratory data at diff erent cutoff s, based on clinical relevance and distribution in the study cohort. Subsequently, a multivariable model was constructed. Multivariable analyses were stratifi ed by center to adjust for center-specifi c eff ects.
Data are presented as median and its interquartile range for continuous variables when applicable. A value of P <0.05 was considered to be statistically signifi cant. All analyses were conducted using IBM SPSS Statistics V.21.0 (Armonk, NY, USA: IBM). Analyses to identify risk factors for major hepatic complications were performed in a multiple imputed database. As a sensitivity analysis, a comparison with complete case analyses was provided. SAS version 9.4 (SAS Institute, Cary, NC, USA) was used to generated 10 imputed data sets (to reduce sampling variability) of laboratory results at baseline and aft er 1, 2, 3, 4, and 5 years of follow-up (SAS Proc MI, MCMC method) ( 33, 34 ) . We assumed missing data occurred at random. Rubin's rules were used for estimation of the parameters and the standard error ( 35, 36 ) . Th e imputation model variables included both those potentially predicting outcome and outcomes themselves. Only the continuous, biochemical values were imputed. Th e biochemical values included for imputation were as follows: alkaline phosphatase; AST; alanine aminotransferase; total bilirubin; albumin; and platelet count. In case of non-normality, the natural logarithm of these variables was used. No categorical or binary variables were imputed.
RESULTS
Study population characteristics
Of the 4,294 UDCA-treated patients in our cohort, status of major hepatic complications was unknown for 959 patients. Th e study cohort comprised 3,335 UDCA-treated patients with PBC. In all, 111 patients with complications before or within the fi rst year of follow-up were excluded from analysis. Th e fi nal population that was used for analyses included 3,224 patients, of whom 91% were female and 73% had an early biochemical disease stage ( Table 1 ). Median follow-up until death, liver transplantation, or censoring was 8.1 years (interquartile range 4.4-12.7) ( Supplementary Table 1 ). During follow-up 150 patients underwent liver transplantation and 337 patients died ( Supplementary Figure 1 ).
Incidence of complications
Hepatic complications were noted in 278 patients ( Figure 1 ). Th e cumulative incidence rate of all fi rst complications was 9.7 cases per 1,000 patient-years. At 3, 5, 10, and 15 years of follow-up, the complication rates in the study population were 1.9%, 3.7%, 9.1%, and 14.8%, respectively ( Figure 1 ). In a majority of 63% ( n =175 patients), the fi rst observed complication was ascites, as opposed to variceal bleeding in 23% ( n =65 patients) and encephalopathy in 8% ( n =22 patients). In a minority of 6% ( n =16 patients) more than one type of complication was noted to occur at the same time. A sensitivity analyses in which patients that were diagnosed with hepatocellular carcinoma before the occurrence non-neoplastic major complications were censored at time of their hepatocellular carcinoma diagnosis, showed a very similar complication rate ( Supplementary Figure 2 ) . When the cumulative incidence was stratifi ed according to the time period of inclusion, we found that the cumulative incidence decreased over time, with a 10-year cumulative complication rate of 13.5% for patients included in or before 1990, 9.3% for patients included between 1990 and 2000, and 5.8% for patients included aft er the year 2000 ( P <0.01 for all; Supplementary Figure 3 ). Patients included in the later time periods more oft en had an early biochemical stage of disease at time of inclusion (75.8% and 74.9%) than before or in 1990 (63.3%). Furthermore, the majority of patients included ≤1990 had an interval between diagnosis of PBC and initiation of UDCA therapy of at least 2 years (56.9%), as opposed to 30.4% of patients included between 1990 and 2000, and 9.4% of patients included aft er 2000 ( Supplementary Table 2 ).
Risk factors for hepatic complications
First, we used univariate Cox regression analyses to identify covariates aft er 12 months of UDCA treatment that were associated with development of hepatic complications. In univariate Cox regression analyses, calendar year of diagnosis, years of untreated PBC diagnosis before starting UDCA therapy, higher AST/alanine aminotransferase ratio, higher APRI, and biochemical non-response to UDCA according to the GLOBE score, were associated with an increased future risk of major hepatic complications. In multivariable analyses, calendar year
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of PBC diagnosis (per 10 years; hazard ratio (HR) 0.73, 95% confi dence interval (CI) 0.60-0.89), a high APRI (HR 5.32, 95% CI 3.82-7.41), and biochemical non-response to UDCA based on the GLOBE score (comprising of age, alkaline phosphatase, bilirubin, albumin, and platelet count; HR 2.68, 95% CI 1.99-3.62) remained independently associated with the risk of major hepatic complications during follow-up (all P <0.01; Table 2 ). A sensitivity analyses on complete cases showed similar results ( Supplementary Table 3 ).
Biochemical non-response and APRI score as predictors of hepatic complications
Both biochemical non-response aft er 1 year of UDCA and an APRI of >0.54 were independent predictors of future hepatic complications. Th e 10-year cumulative incidence of fi rst complications was 32.4% in biochemical non-responders, as opposed to 6.2% in biochemical responders. In patients with an APRI of ≤0.54, the 10-year complication rate was 3.8%, compared to 24.3% in patients with a higher APRI. Patients with both an APRI of ≤0.54 as well as biochemical response aft er 12 months of UDCA, had 3-, 5-, and 10-year complication rates of 0.5%, 1.1% and 3.2%, respectively. In contrast, patients with both an APRI >0.54 as well as biochemical non-response at 12 months had 3-, 5-, and 10-year complication rates of 15.9, 22.1, and 37.4%. In patients with either biochemical non-response and an APRI of ≤0.54, or biochemical response and an APRI of >0.54, the cumulative complication rates were found to be comparable to the overall cohort ( Figure  2 ). Comparable predictive values for biochemical non-response were found when biochemical non-response was defi ned by other criteria ( Table 3 ) .
Hepatic complications and subsequent survival
Overall transplantation-free survival at 1 year was 99.7%, at 3 years 97.3%, at 5 years 94.5%, and at 10 years 85.8%. Figure 3 visualizes the transplantation-free survival rate for patients with and without hepatic complications, estimated using a clock-reset approach ( 37 ) . For patients remaining free of complications the 3-, 5-, and 10-year transplantation-free survival rates were 97.1%, 94.2%, and 85.3%, respectively. In contrast, aft er occurrence of an hepatic complication, these survival rates dropped to 34.7%, 19.2%, and 10.4%, respectively (time-dependent HR 21.5; 20.1-22.8; Figure 3 ). Transplantation-free survival aft er complications diff ered with respect to the nature of the fi rst hepatic complication ( P =0.004; Figure 4 ). Median survival aft er occurrence of variceal bleeding as a fi rst complication was 4.0 years (95% CI 2.9-5.0), Harms et al.
( P <0.001); and serum bilirubin above the upper limit of normal ( P <0.001) remained independently predictive of poor transplantation-free survival ( Supplementary Table 4 ). When transplant-free survival aft er occurrence of a fi rst major complication was stratifi ed according to time period of occurrence of these complications, transplant-free survival complications was signifi cantly shorter for patients that were aff ected earlier in calendar time ( P =0.01), in particular aft er variceal bleeding ( Figure 5 ). At the time of complications serum albumin and bilirubin levels were normal in 17% of the aff ected patients. With a median transplantation-free survival of 7.2 years (95% CI 5.1-9.3), prognosis of patients with normal serum albumin and bilirubin at time of their fi rst hepatic complication was signifi cantly better than the median 1.6 years (95% CI 1.2-1.9) survival of patients with abnormal serum albumin and/or bilirubin ( P <0.001; Supplementary Figure 4 ) .
aft er occurrence of encephalopathy 3.2 years (95%CI 1.8-4.6), aft er occurrence of ascites 1.6 years (95%CI 1.0-2.3) and aft er multiple concurrent complications 0.6 years (95% CI 0.1-1.2). Th e diff erence in survival aft er occurrence of complications was signifi cant for variceal bleeding as compared to ascites ( P =0.001).
No signifi cant diff erences were found with respect to ascites vs. encephalopathy ( P =0.506) or variceal bleeding vs. encephalopathy ( P =0.232).
Prognostic factors at the time of complications
Several laboratory and clinical parameters at the moment of the fi rst hepatic complication proved to be predictive of subsequent transplantation-free survival in univariate analyses. In multivariable Cox regression analysis, a lower calendar year of complications ( P =0.022); serum albumin below the lower limit of normal ( 16, 54 ) . e The median UK-PBC score in this study cohort was −103.3 ( 31 ) . f On the basis of (age-dependent) GLOBE score thresholds ( 12 ) .
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DISCUSSION
In this long-term study of a large, internationally representative cohort of PBC patients treated with UDCA, the current standard therapy, we found that the overall cumulative incidence of major non-neoplastic hepatic complications was 9% after 10 years and 15% after 15 years. The cumulative incidence of these complications decreased over the past decades. Furthermore, in patients responding well to UDCA treatment and a low APRI after 12 months of treatment, the 10-year complication risk was reduced to only 3%, which is in marked contrast with a 10-year risk of 37% in patients with a high APRI and biochemical non-response to UDCA. Our data confirm that these complications are of critical importance in the course of the disease and are predictive of poor survival. Th e decrease in cumulative incidence of major hepatic complications over time may be explained by a number of reasons. First, our data show that over the past decades, patients are increasingly being diagnosed in an early stage of disease ( 2 ) . Second, likely related to the gradual introduction of UDCA and increasing evidence for a therapeutic benefi t of this agent in the last decades of the twentieth century, we found that the interval between diagnosis and initiation of UDCA treatment strongly decreased over time. Also, other developments, such as timely detection Harms et al.
As in other chronic liver disease, the development of hepatic complications is predictive for high mortality in PBC. In agreement with a systematic review assessing survival aft er occurrence of cirrhosis-associated complications across several liver diseases ( 41 ) , median survival aft er the fi rst complication in our cohort was ~2 years. Th e present study also shows that a subgroup of patients develop major hepatic complications in the absence of biochemical features of markedly advanced liver disease. Th e subsequent prognosis of these patients was considerably better than when liver function was more severely compromised.
and widespread primary prophylaxis of variceal bleeding, may have contributed to a decreasing incidence of complications ( 38 ) . In keeping with previous studies on specifi c complications, risk factors we found to be associated with future development of complications are largely the same as those related to transplantfree survival ( 8, 16, 22, 31, 39 ) . Similarly to baseline factors associated with future development of hepatocellular carcinoma ( 40 ) and with risk of overall mortality in PBC ( 30 ), biochemical nonresponse to UDCA therapy proved to be a strong risk factor for the occurrence of major hepatic complications during follow-up. Th is fi nding stresses the clinical importance of evaluating biochemical response to UDCA aft er 1 year of therapy. Interestingly, our data confi rmed the additional prognostic value of APRI independent of biochemical response ( 16 ) . Stratifi cation by both biochemical response and APRI identifi ed a subgroup of ~20% of our cohort with a very low long-term risk of major, non-neoplastic hepatic complications. CI, confi dence interval; HR, hazard ratio. Biochemical response to UDCA was defi ned by previously reported criteria with a threshold defi ning response vs. non-response, calculated by univariate Cox regression analysis. Criteria were calculated after 1 year of follow-up, Toronto criteria were calculated after 2 years of follow-up. Transplant-free survival (%) 
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Our data furthermore indicate that the particular type of hepatic complication is predictive of subsequent survival. Interestingly, patients suff ering from variceal bleeding as the fi rst major complication have a more favorable prognosis than patients who fi rst develop ascites. Th e calendar year of occurrence of these events was an independent predictor of subsequent prognosis, with better outcomes for more recent cases, particularly for variceal bleeding. Improved patient care seems a likely explanation for this observation, which is in agreement with studies reporting improved prognosis aft er variceal bleeding over the last decades ( 42, 43 ) . Ascites is generally considered the most frequent fi rst decompensating event in patients progressing from compensated to decompensated cirrhosis (44) (45) (46) (47) . Our fi nding that ascites is also the most frequent fi rst decompensating event in PBC is in agreement with the results of the classical long-term cohort study performed in Northeast England, reporting that ascites was both the most prevalent cirrhotic complication at the time of diagnosis as well as during follow-up ( 48 ) . Although the development of ascites or other complications is associated with poor prognosis, a subset of ~10% of our patients, particularly those with well-preserved hepatic function, was found to be alive without transplantation aft er 10 years. Th is indicates that major cirrhotic complications can occur relatively early in the course of PBC. Although portal hypertension due to nodular regenerative hyperplasia or other non-cirrhotic architectural histological changes has been reported in PBC (49) (50) (51) , this seems a very rare entity and cirrhosis is the usual underlying cause of portal hypertension ( 21, 52 ) . More detailed characteri zation of the patients in our cohort with favorable long-term prognosis despite major hepatic complications was not the explicit aim of the current study but could be an interesting subject for future study.
Limitations of this study relate mostly to the nature of this study. Although the cumulative database includes prospectively followed-up patients, not all information relevant for this study, such as laboratory data at the time of hepatic events, was uniformly available in the individual data sets. We were able to correct this by means of multiple imputations. Importantly, we do not have data on possible additional major hepatic complications aft er the fi rst event. Th ese data may provide an additional predictive value for However, we speculate that it is unlikely that the main results of the present analyses would have been markedly diff erent if we would have been able to do so. Our study group addressed hepatocellular carcinoma as a major potential complication of PBC in a previous large cohort study ( 40 ) . For this reason it was decided not to reassess this malignancy in the present study, but to concentrate on non-neoplastic, in particular portal hypertension-related complications. However, when analyses were repeated while censoring patients diagnosed with hepatocellular carcinoma during follow-up, the cumulative incidence of major non-neoplastic complications was very comparable. Furthermore, while this is a multicenter, international study, not all ethnicities are well-represented in our cohort. Interestingly, preliminary results of a Japanese study appear to confi rm most of our results, particularly with regard to risk factors and prognosis ( 53 ) . Finally, due to the nature of this study we cannot rule out that a selection bias might exist. Hence, as some relatively specialized centers are included in our cohort, incidence of major hepatic complications might be even lower in a general population of patients with PBC.
In conclusion, this large, international cohort study shows that in UDCA-treated PBC, major hepatic complications are not rare and develop in up to 15% of patients within 15 years of follow-up. On the other hand, our data indicate that the incidence of these complications is decreasing over time, and that nowadays the large majority of patients treated with UDCA will remain free of serious complications such as ascites or variceal bleeding, and that subsequent survival has improved. Biochemical non-response to UDCA and high APRI are important risk factors for major hepatic complications.
